Skip to main content

Advertisement

SpringerLink
Log in

Statins and vitamin D: a friendly association in pre-dialysis patients

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The increased mortality rate observed in patients with chronic kidney disease is related to the high prevalence of cardiovascular disease in this population. Recently, it has been shown that interventional therapy with statins and/or vitamin D could improve the outcomes of these patients. The aim of this study was to identify the risk factors for mortality in a group of patients with chronic kidney disease (stages 4 and 5—pre-dialysis) and verify whether vitamin D and statins could change the outcome. We included 95 patients (mean age—69.4) with stages 4 and 5 (pre-dialysis) of our “low-clearance” outpatient clinic, with an average eGFR of 16.9 ml/min and a mean follow-up of 24.1 months. Several biological, nutritional, laboratory and inflammatory parameters were analysed at baseline. Our population was divided into three groups: G-I, patients not medicated with either vitamin D or statins; G-II, patients medicated with either vitamin D or statins; and G-III, patients medicated with vitamin D and statins. We found (ANOVA) that the serum levels of pre-albumin (P = 0.018) and PTH (P = 0.03) were lower in G-I. Concerning the inflammatory parameters, G-I showed higher levels of hsCRP (P = 0.014) and a trend to higher IL-6 levels (P = 0.077). We found the actuarial survival at 30 months (Kaplan–Meier), to be 56.4% in G-I, 82.3% in G-II and 100% in G-III (log rank = 13.08 P = 0.0014). Using the Cox proportional hazards model, we found that the existence of coronary artery disease (P = 0.0001) and the absence of medication with vitamin D and/or statins (P = 0.005) independently influenced the mortality of our patients. In conclusion, we found, in our study, that patients under vitamin D and statins (with a synergistic effect) were less inflamed and showed a lower mortality rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32(suppl 5):S112–S119

    Article  CAS  PubMed  Google Scholar 

  2. Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic haemodialysis patients. Kidney Int 58:353–362

    Article  CAS  PubMed  Google Scholar 

  3. Kaysen GA (2001) The microinflammatory State in Uremia: causes and potential consequences. J Am Soc Nephrol 12:1549–1557

    CAS  PubMed  Google Scholar 

  4. Stuveling EM, Bakker SJL, Hillege HL et al (2005) Biochemical markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 20:497–508

    Article  CAS  PubMed  Google Scholar 

  5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphorus product with mortality risk in chronic hemodialysis patients. Am J Kidney Dis 31:607–617

    Article  CAS  PubMed  Google Scholar 

  6. Jung HH, Kim S-W, Han H (2006) Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 21:1915–1920

    Article  CAS  PubMed  Google Scholar 

  7. Kovesdy CP, Ahmazadeh S, Anderson JE, Kalantar-Zadeh K (2008) Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73:1296–1302

    Article  CAS  PubMed  Google Scholar 

  8. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH (2001) A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251–1263

    Article  CAS  PubMed  Google Scholar 

  9. Stenvinkel P, Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15:329–337

    Article  PubMed  Google Scholar 

  10. Shoji T, Shinohara K, Kimoto E et al (2004) Lower risk for cardiovascular mortality in oral 1α hidroxy vitamin D3 users in a hemodialysis population. Nephrol Dial Transplant 19:179–184

    Article  CAS  PubMed  Google Scholar 

  11. Teng M, Wolf M, Ofsthun MN et al (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125

    Article  CAS  PubMed  Google Scholar 

  12. Napgal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–687

    Article  Google Scholar 

  13. Patel S, Farragher T, Berry J et al (2007) Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 56:2143–2149

    Article  CAS  PubMed  Google Scholar 

  14. Li YC, Kong J, Wei M et al (2002) 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238

    CAS  PubMed  Google Scholar 

  15. Xiang W, Kong J, Chen S et al (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288(1):E-125–E-132

    CAS  Google Scholar 

  16. Achinger SG, Ayus JC (2005) The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl (95):S37–42

  17. Tan X, Li Y, Liu Y (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17(12):3382–3393

    Article  CAS  PubMed  Google Scholar 

  18. O’Herrin JK, Hullet DA, Heisy DM et al (2002) A retrospective evaluation of 1, 25-dihydroxyvitamin D (3) and its potential effects on renal allograft function. Am J Nephrol 22:515–520

    Article  PubMed  Google Scholar 

  19. Agarwal R, Acharya M, Tian J et al (2003) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823–2828

    Article  Google Scholar 

  20. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin study (4S). Lancet 344:1383–1389

    Google Scholar 

  21. Endo A (1992) the discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569–1582

    CAS  PubMed  Google Scholar 

  22. Davignon J (2004) Beneficial cardiovascular effects of statins. Circulation 109(Suppl III):III39–III43

    PubMed  Google Scholar 

  23. National Kidney Foundation (2002) NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis 39(Suppl 1):S76–S110

    Google Scholar 

  24. Levey AS, Bosh JP, Lewis JB, Greene T, Rogers N, Roth D (1999) For the Modification of Diet in Renal Disease Study Group: a more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Ann Intern Med 130:461–470

    CAS  PubMed  Google Scholar 

  25. Kalantar-Zadeh K, Kleiner M, Dunne E et al (1999) A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant 14:1732–1738

    Article  CAS  PubMed  Google Scholar 

  26. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 suppl 3):S52–S130

    Google Scholar 

  27. (2003) K/DOQI Clinical practice guidelines for managing of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41(suppl 3):39–58

  28. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884–890

    Article  PubMed  Google Scholar 

  29. US Renal Data System (2005) USRDS 2005 annual data report: morbidity and mortality. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda

  30. Shepherd J, Cobbe SM, Ford I et al (1995) For the West of Scotland coronary prevention study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307

    Article  CAS  PubMed  Google Scholar 

  31. (1998) The long-term Intervention with pravastatin in ischemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 339:1349–1357

  32. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) German diabetes and dialysis study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248

    Article  CAS  PubMed  Google Scholar 

  33. Tonelli M, Isles C, Curhan GC et al (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 21:1557–1563

    Article  Google Scholar 

  34. Fellstrom BC, Jardine AG, Schiemedler E et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407

    Article  CAS  PubMed  Google Scholar 

  35. Bradbury BD, Fissell RB, Albert JM et al (2007) Predictors of early mortality among incident US Hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol 2:89–99

    Article  PubMed  Google Scholar 

  36. Kovesdy CP (2007) Regional mortality differences in end-stage renal disease: how far can observational studies take us. Kidney Int 71:11–12

    Article  CAS  PubMed  Google Scholar 

  37. Stenvinkel P, Lindholm B, Heimbürger M, Heimbürger O (2000) Elevated serum levels of soluble adhesion molecules predicts death in predialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 15:1624–1630

    Article  CAS  PubMed  Google Scholar 

  38. Honda H, Qureshi A, Heimbürger O et al (2006) Serum albumin, C-reactive protein, interleukin-6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47:139–148

    Article  CAS  PubMed  Google Scholar 

  39. Panichi V, Paoletti V, Manterano E et al (2006) In vivo and in vitro effects of simvastatin on inflammatory markers in predialysis patients. Nephrol Dial Transplant 21:337–344

    Article  CAS  PubMed  Google Scholar 

  40. Arnaud C, Burger F, Steffens S et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25:1231–1236

    Article  CAS  PubMed  Google Scholar 

  41. Türk S, Akbulut M, Yildiz A et al (2002) Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 90:188–194

    Article  PubMed  Google Scholar 

  42. Giulietti A, van Etten E, Overbragh L et al (2007) Monocytes from type 2 diabetic patients have a pro-inflammatory profile 1, 25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 77:47–57

    Article  CAS  PubMed  Google Scholar 

  43. Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297–304

    Article  CAS  PubMed  Google Scholar 

  44. Grimes DS (2006) Are statins analogues of vitamin D? Lancet 368:83–86

    Article  CAS  PubMed  Google Scholar 

  45. Pérez-Castrillón JL et al (2007) Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99:903–905

    Article  PubMed  Google Scholar 

  46. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168:397–403

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Serviço de Nefrologia, Hospital de Faro, Rua Leão Penedo, 8000, Faro, Portugal

    Pedro L. Neves, Anabela Malho, Ana Cabrita, Ana Pinho, Alexandre Baptista, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira & Ana P. Silva

Authors
  1. Pedro L. Neves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anabela Malho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Cabrita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Pinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandre Baptista
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elsa Morgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marília Faísca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hermínio Carrasqueira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ana P. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pedro L. Neves.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neves, P.L., Malho, A., Cabrita, A. et al. Statins and vitamin D: a friendly association in pre-dialysis patients. Int Urol Nephrol 42, 173–179 (2010). https://doi.org/10.1007/s11255-009-9634-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-009-9634-x

Keywords

Search

Navigation